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COVID-19 is an infectious disease caused by Coronavirus 2 (SARS-CoV-2) that may lead
to a severe acute respiratory syndrome. Such syndrome is thought to be related, at least in
part, to a dysregulation of the immune system which involves three main components:
hyperactivity of the innate immune system; decreased production of type 1 Interferons
(IFN) by SARS-CoV-2-infected cells, namely respiratory epithelial cells and macrophages;
and decreased numbers of both CD4+ and particularly CD8+ T cells. Herein, we describe
how excessive activation of the innate immune system and the need for viral replication in
several cells of the infected organism promote significant alterations in cells’ energy
metabolism (glucose metabolism), which may underlie the poor prognosis of the
disease in severe situations. When activated, cells of the innate immune system
reprogram their metabolism, and increase glucose uptake to ensure secretion of pro-
inflammatory cytokines. Changes in glucose metabolism are also observed in pulmonary
epithelial cells, contributing to dysregulation of cytokine synthesis and inflammation of the
pulmonary epithelium. Controlling hyperglycolysis in critically ill patients may help to reduce
the exaggerated production of pro-inflammatory cytokines and optimise the actions of the
adaptive immune system. In this review, we suggest that the administration of non-toxic
concentrations of 2-deoxy-D-glucose, the use of GLUT 1 inhibitors, of antioxidants such
as vitamin C in high doses, as well as the administration of N-acetylcysteine in high doses,
may be useful complementary therapeutic strategies for these patients, as suggested by
some clinical trials and/ or reports. Overall, understanding changes in the glycolytic
pathway associated with COVID-19 infection can help to find new forms of treatment
for this disease.
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INTRODUCTION
COVID-19 is an infectious disease that emerged in December 2019
inWuhan City, China (Zhu et al., 2020). It is caused by Coronavirus
2 Severe Acute Respiratory Syndrome (SARS-CoV-2) and, although
most infected individuals are asymptomatic, severe acute respiratory
syndrome may develop, and be related, at least in part, to a
dysregulation of the immune system (Mehta et al., 2020; Ye
et al., 2020). While still controversial in its details, such
dysregulation is believed to involve at least three major components.
The first component concerns a hyperactivated state of the
innate immune system, which plays a fundamental role in the
progression of the disease towards more severe forms and a
reserved prognosis. A similar situation was also observed in the
2002–2004 SARS and in the 2012–2015 Middle East Respiratory
Syndrome (MERS) epidemics (Gralinski and Baric, 2015; Lu et al.,
2020). In this context, there is production of several pro-
inflammatory cytokines which induce persistent inflammation,
mainly in the lung (Paces et al., 2020). Most researchers
consider this cytokine dysregulation a “cytokine storm” given
the higher-than-normal levels of detected cytokines (Mehta
et al., 2020; Ye et al., 2020). However, although cytokines such
as IL-6 are increased in COVID-19, their serum levels are clearly
lower than in Acute Respiratory Distress Syndrome (ARDS) from
other causes, and lower than expected in severe cases of COVID-19
(Azoulay et al., 2020; Sinha et al., 2020; Tang et al., 2020).
The second component involves a decrease, or, at least a
significant delay, in production of type 1 Interferons (IFN) by
SARS-CoV-2-infected cells, namely respiratory epithelial cells and
macrophages (Jafarzadeh et al., 2020; Kumar, 2020; Merad and
Martin, 2020). Such a deficiency in type 1 IFN is crucial to
progression of COVID-19 disease since the anti-viral role of
this type of interferons is essential to dealing with the infection
(Jafarzadeh et al., 2020; Paces et al., 2020; Gustine and Jones, 2021).
The final component observed in more severe cases of COVID-
19 involves decreased numbers of both CD4+ and particularly
CD8+ T cells (Leonardi and Proença, 2020), which may also be
dysfunctional and, in the latter cells, also involve hypercytotoxic
states (Chen et al., 2020a; Qin et al., 2020; Schultheiss et al., 2020).
In addition, decreased numbers of Natural Killer (NK) cells in
peripheral blood can also be observed, which further weakens anti-
viral responses, since CD8+ T cells and NK cells are the main
drivers of anti-viral cellular immune responses (Merad andMartin,
2020; Paces et al., 2020).
This mini-review takes into account the three components
mentioned above and will aim at putting forward the concept that
changes in the glycolytic pathway that occur during SARS-CoV-2
infection significantly contribute to the immune dysregulation
observed in severe COVID-19 respiratory infections and also that
specific drug treatments that interfere with such changes in the
glycolytic pathway may be clinically beneficial in infected patients.
THE GLYCOLYTIC PATHWAY
The glycolytic pathway is a metabolic pathway of foremost
importance in supporting life in almost all organisms (aerobic
or anaerobic). It occurs in the cytosol and, under aerobic
conditions, aims to convert the active form of glucose
(glucose-6-phosphate) (C6H11O9P) into pyruvate (C3H4O3) (Li
et al., 2018) (Figure 1). In this pathway, there is cleavage of
glucose (C12O6H12), resulting in the production of potentially
energetic intermediates such as pyruvate and NADH
(C21H29N7O14P2), as shown in the following equation
“C6H12O6 + 2ADP + 2Pi+ 2NAD + → 2C3H4O3 + 2ATP +
2NADH + 2H+” (Chen et al., 2018; Dunn et al., 2016). These
intermediates are subsequently used in the mitochondria, in the
tricarboxylic acid (TCA) cycle for the cell respiration process and
oxidative phosphorylation (OXPHOS), which in turn produces
other intermediates that are used in the electron transport chain
for production of large amounts of adenosine triphosphate (ATP)
(C10H16N5O13P3), which is the most important form of chemical
energy for the cell (and for life) (Figure 1) (Chen et al., 2018). At
the end of the glycolytic pathway, only two molecules of ATP are
produced per glucose molecule, whereas through OXPHOS the
yield rises to 32 molecules of ATP per glucose molecule
(Ostroukhova et al., 2012; Dunn et al., 2016). Under aerobic
conditions, the pyruvate produced in the glycolytic pathway is
transported into the mitochondria and by the action of the
pyruvate dehydrogenase enzyme complex, it is converted into
acetyl CoA (C23H38N7O17P3S), which is used in oxidative
phosphorylation to produce important intermediates for the
electron transport chain (Dunn et al., 2016). Oxygen is used as
the final electron acceptor at the end of the electron transport
chain, and part of this oxygen is transformed into reactive oxygen
species (ROS) by mitochondria, which are the main generators of
ROS, even in a physiological context (Ostroukhova et al., 2012).
In hypoxia situations, changes occur in the energy metabolism
of cells in general, due to the lack or decrease of oxygen supply. In
particular, pyruvate that was converted to acetyl CoA is now
reduced into lactate (C3H5O3) by the action of the lactate
dehydrogenase (LDH) enzyme (Figure 1) (Ostroukhova et al.,
2012). This means that the production of ATP by OXPHOS is
compromised (Ostroukhova et al., 2012), and the decrease in
intracellular oxygen supply reduces the production of ATP by the
electron transport chain. Thus, in hypoxia, cells can only rely on
the glycolytic pathway, which produces just two molecules of
ATP per glucose molecule, a situation that explains the greater
consumption of glucose (hyperglycolysis) as the main source of
energy production (Dunn et al., 2016). It should be highlighted
that hyperglycolysis, that occurs in such cellular hypoxia
situations, is due to reprogramming in the metabolism of
glycolysis, and is characterised both by the production of ATP
exclusively via the glycolytic pathway, and by inhibition of
oxidative phosphorylation (Figure 1) (Li and Zhang, 2016).
Hyperglycolysis or metabolic reprogramming may also occur
in normoxic situations, namely when there is a need for the
immediate use of glucose by cells, in order to increase their
performance in carrying out tasks such as proliferation,
activation, or synthesis of molecules. This strategy is known as
aerobic glycolysis, since the increase in glucose consumption
happens in the presence of oxygen (Li and Zhang, 2016).
In the situations involving metabolic reprogramming
described above, there is thus an enzymatic redefinition that
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involves decreased pyruvate dehydrogenase activity and
increased lactate dehydrogenase (LDH) levels (Figure 1)
(Seheult et al., 2017). In such metabolic reprogramming,
increased expression of hypoxia-1 alpha-inducing factor (HIF-
1α) protein contributes to the previously mentioned decreased
activity of pyruvate dehydrogenase by inhibiting the pyruvate
dehydrogenase complex (Andrejeva and Rathmell, 2017; Kumar,
2020). This explains the inhibition of oxidative phosphorylation,
giving rise to aerobic glycolysis or hyperglycolysis (Figure 1)
(Bergsneider et al., 1997; Andrejeva and Rathmell, 2017; Kumar,
2020).
In inflammatory and septic conditions, as happens in a patient
with severe COVID-19, there is also reprogramming of glucose
metabolism, associated with increased expression of the ubiquitous
sodium-independent glucose transporter 1 (GLUT1) in immune
and non-immune cells, increased expression of glycolytic enzymes,
such as phosphofructokinase-2, as well as inhibition of pyruvate
dehydrogenase enzyme complex by increasing the expression of
HIF-1α, which contributes to the increase in glucose uptake (Icard
et al., 2021). These hyperglycolytic events that occur in response to
stress (i.e., infection-induced stress) also contribute to viral
replication and worsening of inflammation (Kumar, 2020).
Thus, the inhibition of aerobic hyperglycolysis in SARS-COV-2-
infected cells may help to control viral replication and decrease
inflammation, as has been shown in some in vitro studies in which
nontoxic concentrations of 2-deoxy-D-glucose inhibited viral
replication in human, colon carcinoma-derived Caco-2 cells
(Bojkova et al., 2020).
INCREASED GLUCOSE CONSUMPTION BY
CELLS IN SARS-COV-2 INFECTION
SARS-CoV-2 binds via its spike (S) protein to receptors for the
angiotensin-converting enzyme 2 (ACE2) on target cells, and this
protein: receptor complex is internalised by cells, namely
respiratory epithelial or innate immune system cells (Zhang
et al., 2020a). In infected cells, SARS-CoV-2 can induce a set
of changes at various levels, namely considerable changes in the
glycolytic pathway (Ding et al., 2017; Alfano et al., 2021)
(Figure 2). Various mechanisms contribute to this.
First, once inside a cell, the presence of SARS-CoV-2 activates
mechanisms, namely mitochondrial oxidative damage, that
upregulate intracellular production of ROS, which, in turn,
increase cellular injury and cause intracellular stress thereby
forcing the infected cell to have increased glucose
concentrations. Thus, these cells reprogram their glucose
metabolism, and this may involve changes in the final product
of the glycolytic pathway (production of lactate instead of
pyruvate), activation and inhibition of enzymes (activation of
lactate dehydrogenase, and inhibition of pyruvate
dehydrogenase) that favour the infectious scenario (Saleh
et al., 2020). COVID-19 infection-associated intracellular stress
increases endoplasmic reticulum (ER) stress which has been
found to be associated with increased expression of Glucose-
Regulated Protein 78 (GRP78) at the membrane level, in various
settings (e.g., cancer, obesity) (Pfaffenbach and Lee, 2011).
Increased levels of GRP78 are not only important for reducing
FIGURE 1 | Changes that can occur in the glycolytic pathway in COVID-19. When immune cells are resting, glucose is metabolised via the glycolytic pathway,
yielding pyruvate as a product. This substrate is subsequently used in the tricarboxylic acid cycle (TCA) to form intermediates that will be processed by oxidative
phosphorylation to produce 32 molecules of ATP, for each molecule of glucose. When immune cells are activated or hypoxic, glucose metabolism is reprogrammed.
There is an increase in the type 1 alpha hypoxia-inducing factor (HIFa), which inhibits pyruvate dehydrogenase enzyme complex (PDH). Pyruvate is thus
transformed into lactate by the action of lactate dehydrogenase (LDH). But this mechanism motivates the capture of more glucose for the synthesis of further ATP
molecules. There is also activation of the pentose phosphate (PPP) pathway that produces ribose and NADPH. The latter can be used by immune cells through the
actions of NADPH oxidase to produce reactive oxygen species (ROS).
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ER oxidative stress but translocation of this protein to the
membrane also aims to meet the increased demand for
glucose inside the infected and stressed cell, since GRP78
contributes to increased glucose uptake into cells (Madhavan
and Nagarajan, 2020). In fact, elevated GRP78 levels are
significantly higher in COVID-19 infected patients with or
without pneumonia than in healthy controls and also tend to
be higher than in COVID-negative patients with pneumonia
(Sabirli et al., 2021).
Second, patients with severe SARS-CoV-2 infection have been
shown to have higher levels of lactate dehydrogenase (LDH) in
the peripheral blood compared to patients with mild or moderate
disease (Chen et al., 2020b; Mo et al., 2020; Tian et al., 2020). For
this reason, LDH is used as one of several relevant parameters to
assess the severity of COVID-19 (Zhang et al., 2020b). The
augmented levels of LDH in COVID-19 are related to an
increase in the production of lactate, which means that
changes in the glycolytic pathway and/or low oxygen
conditions occur in cells in the context of infection and/or
activation (Ding et al., 2017; Strachecka et al., 2019; Farhana
and Lappin, 2020; Morassi et al., 2020). In SARS-CoV 2 infection,
with abrupt lung involvement, there is a decrease in oxygen
supply in lung cells due to inflammatory events resulting from the
infection (Jahani et al., 2020; Serebrovska et al., 2020; Ye et al.,
2020) This situation leads to a set of changes in the glycolytic
pathway, as well as increased glucose uptake, that impair cell
function, thereby worsening events that eventually lead to
multiorgan dysfunction, as increased glucose uptake promotes
ideal conditions for an inflammatory environment and ROS
production (Paces et al., 2020).
CONSEQUENCES OF GLUCOSE
METABOLISM REPROGRAMMING IN
INFECTED LUNG EPITHELIAL CELLS
Pulmonary epithelial cells infected by SARS-COV 2 also have an
increased expression of HIF-1 a which is closely associated with
metabolic reprogramming (Kumar, 2020). In these cells,
metabolic reprogramming increases consumption of glucose
(Figure 2) and as a consequence, it augments local secretion
of proinflammatory cytokines (Neufeldt et al., 2020) that are
responsible for the infiltration of monocytes and neutrophils into
the lungs. On the other hand, the virus inhibits the secretion of
FIGURE 2 | Conceptual model of SARS-CoV-2-associated changes in the glycolytic pathway and its consequences on COVID-19 in critically ill patients. Viral
infection activates the innate immune system, namely M1 macrophages. Activation of macrophages promotes metabolic changes for their effective action, including an
increase in consumption of glycolysis (hyperglycolysis) and a change in the strategy for ATP synthesis (metabolic reprogramming). These changes favour the production
of ROS and worsen inflammation. Hyperglycolysis may also promote an increase in serum lactate. SARS-CoV-2 infection also affects epithelial lung cells by making
them increase their glucose consumption, which makes viral replication viable. Infected epithelial cells also show enhanced presentation of viral antigens to T
lymphocytes (particularly CD8+ T cells), and NK cells are also affected, with both cell types becoming more chronically activated. These events promote exhaustion and
subsequent apoptosis of T and NK cells, thereby contributing to peripheral lymphopenia. Drugs that may eventually be used as complementary treatment of severe
COVID-19 infection by inhibition infection-associated hyperglycolysis include 2-deoxy-D-glucose (2DG), N-acetylcysteine or GLUT1 inhibitors. Administration of 2DG
inhibits hyperglycolysis in innate immune system cells such as macrophages; on the other hand, the administration of N -acetylcysteine inhibits the increase in ROS
production by activating glutathione (see therapeutic strategies section). The action of GLUT1 inhibitors is not shown but involves blocking glucose uptake in activated
and infected immune system and epithelial cells.
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type 1 IFN in human airway epithelial cells (Vanderheiden et al.,
2020), which reduces antiviral mechanisms and may also
contribute to worsening of the inflammatory and septic
condition (Kumar, 2020).
In general, in severe situations of SARS-CoV infection,
metabolic reprogramming in human airway epithelial cells
promotes increased glucose uptake and increased oxidative
stress that culminates in increased lactate production, and
mitochondrial damage, as well as dysregulation of the innate
immune system (including overactivation and functional
dysregulation of the innate immune system, as well as
functional depletion and dysregulation of T cells), which
results in a poor prognosis in critically ill patients (Li et al., 2018).
CHANGES IN THE GLYCOLYTIC PATHWAY
IN IMMUNE CELLS IN SARS-COV-2
INFECTION
Some in vitro studies have shown that cultures of SARS-CoV-2-
infected bronchoalveolar lavage monocytes from patients with
COVID-19 have upregulated expression of genes associated with
glycolysis (Codo et al., 2020). In addition, the same study also
showed that SARS-CoV-2 infection, but not infection with the
human H1N1 influenza A or respiratory syncytial virus,
specifically stimulated glycolysis and increased glycolytic
capacity and glycolytic reserve in monocytes (Codo et al., 2020).
The production of cytokines in immune cells such as
macrophages, dendritic cells or neutrophils, as well as
activation of these cells is intrinsically linked to
reprogramming of energy metabolism (Figure 2) (Patel et al.,
2019; Codo et al., 2020), and this also occurs in SARS-CoV-2
infection (Kumar, 2020). Activated macrophages undergo
metabolic reprogramming, by switching from oxidative
phosphorylation to aerobic glycolysis, a strategy that proves to
be more profitable and effective for ATP production required for
the secretion of cytokines and all other effector actions that these
cells need to perform in the case of infection, namely antigen
presentation to T cells (Icard et al., 2021).
Thus, SARS-CoV-2 infection activates the innate immune
system and, if this process becomes uncontrolled, it can result
in the dysregulation of cytokine production (Figure 2), involving
increased production of pro-inflammatory cytokines, namely
interleukin-6 (IL-6), IL-8, TNF- a and others, which
contribute to the development of ARDS (Fu et al., 2020). In
the context of ARDS it is accepted that there is a decrease in tissue
oxygen which, if severe, is reflected in cellular hypoxia, thereby
further contributing to metabolic reprogramming in immune
cells (Jahani et al., 2020; Serebrovska et al., 2020).
However, in some situations, the alteration in the glycolytic
pathway does not occur towards production of aerobic glucose,
which induces a more efficient immune response, but rather
towards oxidative phosphorylation, which compromises and
delays this response. In this sense, the virus inhibits molecular
signaling mechanisms that activate aerobic glycolysis, thereby
impairing the synthesis of type 1 IFN and contributing towards
dysregulated production of pro-inflammatory cytokines, a
scenario observed not only in infected epithelial cells, but also
in infected dendritic cells and peripheral blood mononuclear cells
(Gardinassi et al., 2020).
Furthermore, persistent inflammation mediated by the innate
immune system, namely M1macrophages, as well as the constant
presentation of viral antigens to CD8+ cytotoxic T cells contribute
to the exhaustion of the latter cells (Figure 2), and, as
consequence, their energy metabolism also changes from
aerobic glucose to oxidative phosphorylation (Fenwick et al.,
2019; Kumar, 2020). In fact, in infected cytotoxic CD8+
T cells, the production of ATP ends up being provided by
oxidative phosphorylation, in contrast to aerobic glycolysis.
This situation is detrimental to infected cells due to the fact
that they produce more ROS via mitochondria, may become
more dysfunctional and enter apoptosis (Fenwick et al., 2019).
WILL THERE BE LACTIC ACIDOSIS IN
SARS-COV-2 INFECTION DUE TO
ALTERATION OF THE GLYCOLYTIC
PATHWAY?
Changes in glucose metabolism that promote hyperglycolysis lead
to the formation of significant amounts of lactate (Figure 1)
(Brooks, 2018). Lactate production can have differential effects on
immune cells, namely indirect inhibition of production of type 1
IFN in macrophages (Kumar, 2020; Zhang et al., 2019). These
effects would also be expected in patients with SARS-CoV-2
infection, because of the changes in the glycolytic pathway that
promote overactivation of the innate immune system (Figure 2)
(Fenwick et al., 2019; Ye et al., 2020). High levels of lactate could
also be expected due to pulmonary impairment in critically ill
patients with SARS-CoV-2. However, lactate does not seem to be
associated with a poor prognosis and progression of the disease,
since its serum levels are not increased in the overwhelming
majority of critically ill patients with COVID-19 (Mo et al., 2020;
Tang et al., 2020). Recently, a retrospective study that aimed to
identify acid-base disorders in patients with COVID-19 identified
only one patient whose metabolic acidosis was caused by a slight
increase in peripheral blood lactate, in a sample of 211 patients
(Alfano et al., 2021). In fact, the vast majority of studies do not
report such a condition in patients with severe COVID-19
infection who are hospitalized in ICU wards, even when LDH
levels are increased (Zhang et al., 2019). This is an interesting
situation that could lead to a discussion about the effects of
hypoxia and hyperglycolysis in COVID-19 from a metabolic
point of view, and raise the question of why there is no
detectable lactic acidosis in the peripheral blood of critically ill
patients with COVID-19. The mechanism behind the lack of an
increase in lactate levels is not known, but one hypothesis may be
that produced lactate can be rapidly consumed by the lactate-
producing cell as it is used, for instance, for binding to
mitochondrial antiviral-signaling protein (MAVS) which may
result in decreased type 1 IFN production as was seen in HEK-293
human kidney cell lines (Zhang et al., 2019). On the other hand,
there is also the possibility that the non-accumulation of lactate in
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the bloodstream may be due to its consumption by the liver and
kidneys, through the Cori cycle, allowing the production of more
glucose. The increase in LDH could reinforce this idea, since this
enzyme is also involved in the conversion of lactate to pyruvate in
the Cori cycle (Marik and Bellomo, 2013; Gurung and Jialal, 2020;
Levitt et al., 2020; Yang et al., 2020).
CHANGES IN THE GLYCOLYTIC PATHWAY
PROMOTE REACTIVE OXYGEN SPECIES
PRODUCTION IN SARS-COV-2 INFECTION
As was previously mentioned, hyperglycolysis leads to
overproduction of ROS (Figure 2). Several cells in different
organs, as well as macrophages and neutrophils have an
enzyme complex called NADPH oxidase (Figure 1) (Baillet
et al., 2017) Among other functions, this transmembrane
complex produces ROS, thereby acting as a relevant source of
such oxygen radicals in infectious processes (Baillet et al., 2017).
NADPH oxidase uses NADPH produced in the pentose
phosphate pathway (PPP) as an electron donor for the
production of ROS (Figure 1) (Andrejeva and Rathmell, 2017;
Baillet et al., 2017). As hyperglycolysis promotes an increase in
the production of glucose-6-phosphate, an intermediate of the
glycolytic pathway that is used in the pentose phosphate pathway
for the production of ribose-5-phosphate and NADPH, there will
necessarily be an increase in ROS production by NADPH oxidase
(Figure 1) (Baillet et al., 2017).
The increase in ROS by activating NADPH oxidase further
stimulates hyperglycolysis to produce more ATP, and the
production of ATP in turn further activates NADPH oxidase.
ATP is used to phosphorylate the components of NADPH
oxidase, thus leading to its activation. Therefore, the assembly
of the enzyme complex is improved to increase production of
ROS (Baillet et al., 2017). In addition, there is a process of mutual
activation between hyperglycolysis and NADPH oxidase that is
mediated by phosphofrutokinase-2 (Batushansky et al., 2019).
It is generally accepted that these situations of hyperglycosis in
COVID-19 infection augment the activation of the immune
system and worsen inflammatory response, namely via ROS
production (Saleh et al., 2020; Icard et al., 2021). Thus, since
there is a considerable increase in ROS in severe COVID-19, and
little or no production of natural antioxidants by the body, the use
of antioxidants could be part of the therapeutic protocols of
critically ill patients with COVID-19. In fact, an epidemiological
analysis has recently suggested that an anti-oxidant-rich dietary
approach may enhance Nuclear factor (erythroid-derived 2)-like
2 (Nrf-2)-associated antioxidant effect, thereby contributing to
mitigation of the severity of COVID-19 infection (Bousquet et al.,
2020; Bousquet et al., 2021).
THERAPEUTIC STRATEGIES
Increased glucose consumption (hyperglycolysis), as part of
metabolic reprogramming in which there is enzymatic
redefinition, appears to be the basis for severity and poor
prognosis in critically ill patients infected with SARS-COV-2.
Thus, controlling hyperglycolysis in critically ill patients
would help to control the dysregulated or exaggerated
production of pro-inflammatory cytokines and optimise the
action of the adaptive immune system. In this context, the
administration of non-toxic concentrations of 2-deoxy-
D-glucose (2-DG) may be a strategy for minimizing events
resulting from increased glucose consumption. 2-DG is a
glucose analogue which inhibits the glycolytic pathway,
through the inhibition of phosphoglucoisomerase. Thus,
there will be no formation of glucose-6-phosphate, which is
a crucial intermediate for the continuity of the glycolytic
pathway (Saleh et al., 2020; Verma et al., 2020). This mode
of action makes 2-DG a possibly useful drug for inhibition of
metabolic reprograming which also occurs in cancer, resulting
in decreased glucose consumption and inhibition of the
glycolytic pathway in cancer cells (Woodward and Cramer,
1952). Studies carried out in vitro and in murine models
showed that 2-DG may induce antitumor CD8+ T cell-
mediated cytotoxicity and increased production of IFN-g
(Sasaki et al., 2021). In addition, 2-DG in association with
radiotherapy also has other immune effects by increasing cell
membrane expression of molecules that are relevant to antigen
presentation (MHC II and CD86) by dendritic cells and
reducing production of the pro-inflammatory cytokine
TNFα (Farooque et al., 2014). All of these actions may be
beneficial in the context of severe COVID-19 infection.
However, evidence of clinical benefit is warranted in this
context. Although 2-DG monotherapy may need to involve
high doses and toxicity, small phase I and phase II clinical
trials in patients with glioblastoma showed that combined
treatment of 2-DG and radiotherapy was well tolerated,
moderately improved survival, and improved quality of life
(Mohanti et al., 1996; Singh et al., 2005), although there were
problems with study design and definition of endpoints in
these studies (Mohanti et al., 1996; Singh et al., 2005; Halder
and Mehta, 2021). Thus, various aspects regarding safety and
efficacy of 2-DG as complementary treatment both in cancer
and in infectious diseases such as COVID-19 still have to be
addressed by robust, randomized, double-blind, placebo-
controlled phase III clinical trials. Currently, at least one
phase II clinical trial aiming at studying safety and efficacy
of 2-DG in COVID-19 patients is underway (CTRI/2020/06/
025,664; Cochrane Central register of Controlled Trials).
On the other hand, pharmacological strategies such as the use
of GLUT 1 inhibitors (GLUT-1i) aimed at inhibiting glucose
transporters could be evaluated in the treatment of critically ill
patients, since there is an increase in the expression of GLUTs in
immune and non-immune cells in these patients. In fact, the use
of glucose inhibitors as a therapeutic strategy in other infectious
diseases (e.g., Zika virus or Human T cell Leukemia Virus
infections) and in various types of cancer cells has been
documented in vitro by other authors (Manel et al., 2003;
Dominguez Rieg and Rieg, 2019; Lin et al., 2019; Reckzeh and
Waldmann, 2020; Cao et al., 2021) but data are necessary in the
context of the possible use of GLUT-1i as complementary therapy
in severe COVID-19 infection.
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Changes in the glycolytic pathway in critically ill, SARS-COV-
2-infected patients lead to increased production of ROS and a
decrease in compounds that control such radicals, such as
glutathione. Based on this scenario, the use of antioxidants
such as vitamin C in high doses as a therapeutic adjuvant in
critically ill patients with COVID-19 has been shown to be a
promising strategy. A prospective, randomised double-blind
clinical trial with a sample of 308 critically ill COVID-19
patients, demonstrated that the use of high doses of vitamin C
improved lung function and reduced mortality from multiple
organ failure. It has been shown, despite the need for further
studies, that this strategy would help to reduce ARDS events and
multiorgan damage caused by excess ROS from alterations in the
glycolytic pathway (Liu et al., 2020).
On the other hand, still with the perspective of mitigating
ROS-induced events, another interesting therapeutic approach
would be the administration of N-acetylcysteine in high doses.
This compound is a reduced glutathione (GSH) intermediate
(Suhail et al., 2020). Its use aims to increase GSH (a natural
antioxidant) levels in the body, since such levels are decreased in
critically ill COVID-19 patients (Bartolini et al., 2021; Karkhanei
et al., 2021). Beneficial effects of N-acetylcysteine have been
demonstrated in clinical trials in various infections, including
influenza and influenza-like infections, namely H1N1 influenza
pneumonia or even community acquired pneumonia (De Flora
et al., 1997; Zhang et al., 2018). In COVID-19, administration of
N-acetylcyteine, alone or together with other types of
supplementation may be beneficial in patients with different
degrees of severity of SARS-CoV-2 infection, as suggested by a
few small-sized, non-controlled clinical interventional studies or
case reports (De Flora et al., 2020; Avdeev et al., 2021;Wong et al.,
2021), although these results may not apply to patients with
SARS-CoV-2-induced ARDS (de Alencar et al., 2021; Taher et al.,
2021), and still need to be more robustly analysed in larger,
randomised, placebo-controlled studies.
CONCEPTUAL MODEL
A general conceptual model of all COVID-19-associated changes
in glycolytic pathways as well as potential points for therapeutic
interventions is shown in Figure 2.
CONCLUSION
Events related to changes in the glycolytic pathway in COVID-19
infection may explain the underlying pathology and severity of
some cases of the disease. However, although there is clear
scientific evidence showing changes in glycolysis in COVID-19
infection, there is still little evidence linking such changes to
worse prognosis of COVID-19. Thus, the current review clearly
shows that such an association should be considered in future
research in this context.
Furthermore, there seems to be a relationship between
hyperglycolysis and dysregulation of the immune system, as
well as cellular damage. However, further studies are needed
to consolidate these ideas and, perhaps, to find therapeutic targets
that can mitigate the deleterious events that arise from this
context.
Since there is a considerable increase in ROS in severe
COVID-19, and little or no production of natural antioxidants
by the body, we think that perhaps the use of antioxidants could
be part of the therapeutic protocols of critically ill patients with
COVID-19.
AUTHOR CONTRIBUTIONS
AS structured and wrote the mini-review and carried out all
relevant searches. AM, PPov, PP, and LT-B helped with writing
the mini-review and offered relevant suggestions for improvement.
REFERENCES
Alfano, G., Ferrari, A., Fontana, F., Mori, G., Magistroni, R., Guaraldi, G., et al.
(2021). Fc 025Acid Base Disorders in Covid-19. Int. Urol. Nephrol. 36, 1–6.
doi:10.1007/s11255-021-02855-110.1093/ndt/gfab145.001
Andrejeva, G., and Rathmell, J. C. (2017). Similarities and Distinctions of Cancer
and Immune Metabolism in Inflammation and Tumors. Cel Metab. 26 (1),
49–70. doi:10.1016/j.cmet.2017.06.004
Avdeev, S. N., Gaynitdinova, V. V., Merzhoeva, Z. M., and Berikkhanov, Z. G.-M.
(2021). N-acetylcysteine for the treatment of COVID-19 among hospitalized
patients. J. Infect. S0163-4453 (21), 00329–337. doi:10.1016/j.jinf.2021.07.003
Azoulay, E., Zafrani, L., Mirouse, A., Lengliné, E., Darmon, M., and Chevret, S.
(2020). Clinical phenotypes of critically ill COVID-19 patients. Intensive Care
Med. 46 (8), 1651–1652. doi:10.1007/s00134-020-06120-4
Baillet, A., Hograindleur, M. A., El Benna, J., Grichine, A., Berthier, S., Morel, F.,
et al. (2017). Unexpected function of the phagocyte NADPH oxidase in
supporting hyperglycolysis in stimulated Neutrophils: Key Role of 6-
phosphofructo-2-kinase. FASEB j. 31 (2), 663–673. doi:10.1096/fj.201600720R
Bartolini, D., Stabile, A. M., Bastianelli, S., Giustarini, D., Pierucci, S., Busti, C., et al.
(2021). SARS-CoV2 infection impairs the metabolism and Redox function of
cellular glutathione. Redox Biol. 45, 102041. doi:10.1016/j.redox.2021.102041
Batushansky, A., Matsuzaki, S., Newhardt, M. F., West, M. S., Griffin, T. M.,
and Humphries, K. M. (2019). GC-MS metabolic profiling Reveals
fructose-2,6-bisphosphate Regulates branched chain amino acid
metabolism in the heart during fasting. Metabolomics 15 (2), 18.
doi:10.1007/s11306-019-1478-5
Bergsneider, M., Hovda, D. A., Shalmon, E., Kelly, D. F., Vespa, P. M., Martin, N.
A., et al. (1997). Cerebral hyperglycolysis following severe traumatic brain
injury in humans: a positron emission tomography study. J. Neurosurg. 86 (2),
241–251. Retrieved Feb 15, 2021, from. doi:10.3171/jns.1997.86.2.024https://
thejns.org/view/journals/j-neurosurg/86/2/article-p241.xml
Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., et al. (2020).
Proteomics of SARS-CoV-2-infected host cells Reveals therapy targets. Nature
583 (7816), 469–472. doi:10.1038/s41586-020-2332-7
Bousquet, J., Anto, J. M., Czarlewski, W., Haahtela, T., Fonseca, S. C., Iaccarino, G.,
et al. ARIA Group (2020). Cabbage and fermented vegetables: from death Rate
heterogeneity in countries to candidates for mitigation strategies of severe
COVID-19. Allergy 76, 735–750. doi:10.1111/all.14549
Bousquet, J., Le Moing, V., Blain, H., Czarlewski, W., Zuberbier, T., de la Torre, R.,
et al. (2021). Efficacy of broccoli and glucoraphanin in COVID-19: From
hypothesis to proof-of-concept with three experimental clinical cases. World
Allergy Organ. J. 14, 100498. doi:10.1016/j.wa10.1016/j.waojou.2020.100498
Brooks, G. A. (2018). The Science and Translation of Lactate Shuttle Theory. Cel
Metab. 27 (4), 757–785. doi:10.1016/j.cmet.2018.03.008
Cao, S., Chen, Y., Ren, Y., Feng, Y., and Long, S. (2021). GLUT1 biological function
and inhibition: Research advances. Future Med. Chem. 13, 1227–1243.
doi:10.4155/fmc-2021-0071
Frontiers in Chemistry | www.frontiersin.org September 2021 | Volume 9 | Article 6851967
Santos et al. Hyperglycolysis Underlying COVID-19 Disease Severity
Chen, G., Wu, D., Guo,W., Cao, Y., Huang, D., Wang, H., et al. (2020). Clinical and
immunological features of severe and moderate coronavirus disease 2019.
J. Clin. Invest. 130, 2620–2629. doi:10.11172/JCI13724410.1172/jci137244
Chen, W., Gong, P., Guo, J., Li, H., Li, R., Xing, W., et al. (2018). Glycolysis
Regulates Pollen Tube Polarity via Rho GTPase Signaling. Plos Genet. 14 (4),
e1007373. doi:10.1371/journal.pgen.1007373
Chen, X.-Y., Huang, M.-Y., Xiao, Z.-w., Yang, S., and Chen, X.-Q. (2020). Lactate
dehydrogenase elevations is associated with severity of COVID-19: a meta-
analysis. Crit. Care 24, 459. doi:10.1186/s13054-020-03161-5
Codo, A. C., Davanzo, G. G., Monteiro, L. d. B., de Souza, G. F., Muraro, S. P.,
Virgílio-da-Silva, J. V., et al. (2020). Elevated Glucose Levels Favor SARS-CoV-
2 Infection and Monocyte Response through a HIF-1α/Glycolysis-dependent
Axis. Cel Metab. 32, 437–446. doi:10.1016/j.cmet.2020.07.007
de Alencar, J. C. G., Moreira, C. L., Müller, A. D., Chaves, C. E., Fukuhara, M. A., da
Silva, E. A., et al. (2021). Double-blind, Randomized, Placebo-controlled Trial
with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome
Caused by Coronavirus Disease 2019 (COVID-19). Clin. Infect. Dis. 72,
e736–e741. doi:10.1093/cid/ciaa1443
De Flora, S., Balansky, R., and La Maestra, S. (2020). Rationale for the Use of N
-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB
j. 34 (10), 13185–13193. doi:10.1096/fj.202001807
De Flora, S., Grassi, C., and Carati, L. (1997). Attenuation of influenza-like
symptomatology and improvement of cell-mediated immunity with long-
term N-acetylcysteine treatment. Eur. Respir. J. 10, 1535–1541. doi:10.1183/
09031936.97.10071535
Ding, J., Karp, J. E., and Emadi, A. (2017). Elevated Lactate Dehydrogenase (LDH)
Can Be a Marker of Immune Suppression in Cancer: Interplay between
Hematologic and Solid Neoplastic Clones and Their Microenvironments.
Cbm 19 (4), 353–363. doi:10.3233/CBM-160336
Dominguez Rieg, J. A., and Rieg, T. (2019). What does sodium-glucose co-
transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes.
Metab. 21 (Suppl. 2Suppl 2), 43–52. doi:10.1111/dom.13630
Dunn, J.-O., Mythen, M., and Grocott, M. (2016). Physiology of Oxygen Transport.
BJA Edu. 16 (10), 341–348. doi:10.1093/bjaed/mkw012
Farhana, A., and Lappin, S. L. (2020). Biochemistry, Lactate Dehydrogenase
(LDH). StatPearls, 32491468.
Farooque, A., Singh, N., Adhikari, J. S., Afrin, F., and Dwarakanath, B. S. R. (2014).
Enhanced antitumor immunity contributes to the Radio-sensitization of
Ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice.
PLoS One 9, e108131. doi:10.1371/journal.pone.0108131
Fenwick, C., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., et al. (2019). T-
cell exhaustion in HIV infection. Immunol. Rev. 292 (1), 149–163. doi:10.1111/
imr.12823
Fu, L., Wang, B., Yuan, T., Chen, X., Ao, Y., Fitzpatrick, T., et al. (2020). Clinical
characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic
Review and meta-analysis. J. Infect. 80 (6), 656–665. doi:10.1016/
j.jinf.2020.03.041
Gardinassi, L. G., Souza, C. O. S., Sales-Campos, H., and Fonseca, S. G. (2020).
Immune and metabolic signatures of COVID-19 Revealed by transcriptomics
data Reuse. Front. Immunol. 11, 1636. doi:10.3389/fimmu.2020.01636
Gralinski, L. E., and Baric, R. S. (2015). Molecular pathology of emerging
coronavirus infections. J. Pathol. 235 (2), 185–195. doi:10.1002/path.4454
Gurung, P., and Jialal, I. (2020). “Plasma Glucose,” in StatPearls. Treasure Island
(FL) (United States: StatPearls Publishing), 2.
Gustine, J. N., and Jones, D. (2021). Immunopathology of Hyperinflammation in
COVID-19. Am. J. Pathol. 191 (1), 4–17. doi:10.1016/j.ajpath.2020.08.009
Halder, S., and Mehta, A. K. (2021). 2-Deoxy-D-glucose: is this the final cure for
COVID-19: or yet another mirage?. Eur. Rev. Med. Pharmacol. Sci. 25,
4448–4450. doi:10.26355/eurrev_202107_26234
Icard, P., Lincet, H., Wu, Z., Coquerel, A., Forgez, P., Alifano, M., et al. (2021). The
Key Role of Warburg effect in SARS-CoV-2 Replication and associated
inflammatory Response. Biochimie 180, 169–177. doi:10.1016/
j.biochi.2020.11.010
Jafarzadeh, A., Chauhan, P., Saha, B., Jafarzadeh, S., and Nemati, M. (2020).
Contribution of monocytes and macrophages to the local tissue inflammation
and cytokine storm in COVID-19: Lessons from SARS and MERS, and
potential therapeutic interventions. Life Sci. 257, 118102. doi:10.1016/
j.lfs.2020.1181010.1016/j.lfs.2020.118102
Jahani, M., Dokaneheifard, S., and Mansouri, K. (2020). Hypoxia: A Key feature of
COVID-19 launching activation of HIF-1 and cytokine storm. J. Inflamm. 17
(1), 33. doi:10.1186/s12950-020-00263-3
Karkhanei, B., Talebi Ghane, E., andMehri, F. (2021). Evaluation of oxidative stress
level: total antioxidant capacity, total oxidant status and glutathione activity in
patients with COVID-19. New Microbes and New Infections 42, 100897.
doi:10.1016/j.nmni.2021.100897
Kumar, V. (2020). How could we forget immunometabolism in SARS-CoV2
infection or COVID-19?. Int. Rev. Immunol. 40, 72–107. doi:10.1080/
08830185.2020.1840567
Leonardi, A. J., and Proença, R. B. (2020). Akt-Fas to quell aberrant T cell
differentiation and apoptosis in Covid-19. Front. Immunol. 11, 600405.
doi:10.3389/fimmu.2020.600405
Levitt, D. G., Levitt, J. E., and Levitt, M. D. (2020). Quantitative Assessment of
Blood Lactate in Shock: Measure of Hypoxia or Beneficial Energy Source.
Biomed. Res. Int. 2020, 1–24. doi:10.1155/2020/2608318
Li, Y., Lu, B., Sheng, L., Zhu, Z., Sun, H., Zhou, Y., et al. (2018). Hexokinase 2-
Dependent Hyperglycolysis Driving Microglial Activation Contributes to
Ischemic Brain Injury. J. Neurochem. 144 (2), 186–200. doi:10.1111/
jnc.14267
Li, Z., and Zhang, H. (2016). Reprogramming of glucose, fatty acid and amino acid
metabolism for cancer progression. Cell. Mol. Life Sci. 73 (2), 377–392.
doi:10.1007/s00018-015-2070-4
Lin, S.-C., Chen, M.-C., Liu, S., Callahan, V. M., Bracci, N. R., Lehman, C. W., et al.
(2019). Phloretin inhibits Zika virus infection by interfering with cellular
glucose Utilisation. Int. J. Antimicrob. Agents 54, 80–84. doi:10.1016/
j.ijantimicag.2019.03.017
Liu, F., Zhu, Y., Zhang, J., Li, Y., and Peng, Z. (2020). Intravenous high-dose
vitamin C for the treatment of severe COVID-19: study protocol for a
multicentre Randomised controlled trial. BMJ Open 10 (7), e039519.
doi:10.1136/bmjopen-2020-039519
Lu, L., Zhong, W., Bian, Z., Li, Z., Zhang, K., Liang, B., et al. (2020). A comparison
of mortality-Related Risk factors of COVID-19, SARS, and MERS: A systematic
Review and meta-analysis. J. Infect. 81 (4), e18–e25. doi:10.1016/j.10.1016/
j.jinf.2020.07.002
Madhavan, S., and Nagarajan, S. (2020). GRP78 and Next generation cancer
hallmarks: An Underexplored molecular target in cancer chemoprevention
Research. Biochimie 175, 69–76. doi:10.1016/j.biochi.2020.05.005
Manel, N., Kim, F. J., Kinet, S., Taylor, N., Sitbon, M., and Battini, J.-L. (2003). The
Ubiquitous glucose transporter GLUT-1 is a Receptor for HTLV. Cell 115,
449–459. doi:10.1016/s0092-8674(03)00881-x
Marik, P., and Bellomo, R. (2013). Lactate clearance as a target of therapy in sepsis:
a flawed paradigm. OA Crit. Care 1 (1), 3. doi:10.13172/2052-9309-1-1-431
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., and Manson,
J. J. (2020). COVID-19: consider cytokine storm syndromes and
immunosuppression. The Lancet 395, 1033–1034. doi:10.1016/S0140-
6736(20)30628-0
Merad, M., and Martin, J. C. (2020). Pathological inflammation in patients with
COVID-19: a Key Role for monocytes and macrophages.Nat. Rev. Immunol. 20
(6), 355–362. doi:10.1038/s41577-020-0331-4
Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., et al. (2020). Clinical
Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China. Clin.
Infect. Dis., 16, 2020. ciaa270. doi:10.1093/cid/ciaa270
Mohanti, B. K., Rath, G. K., Anantha, N., Kannan, V., Das, B. S., Chandramouli, B.
A. R., et al. (1996). Improving cancer Radiotherapy with 2-deoxy-D-glucose:
Phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat.
Oncology*Biology*Physics 35, 103–111. doi:10.1016/s0360-3016(96)85017-6
Morassi, M., Bagatto, D., Cobelli, M., D’Agostini, S., Gigli, G. L., Bnà, C., et al.
(2020). Stroke in Patients with SARS-CoV-2 Infection: Case Series. J. Neurol.
267 (8), 2185–2192. doi:10.1007/s00415-020-09885-2
Neufeldt, C. J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.-Y., Plociennikowska, A.,
et al. (2020). SARS-CoV-2 infection induces a pro-inflammatory cytokine
Response through cGAS-STING and NF-κB. bioRxiv. doi:10.1101/
2020.07.21.212639
Ostroukhova, M., Goplen, N., Karim, M. Z., Michalec, L., Guo, L., Liang, Q., et al.
(2012). The Role of low-level lactate production in airway inflammation in
asthma. Am. J. Physiol. Lung Cel Mol Physiol 302 (3), L300–L307. doi:10.1152/
ajplung.00221.2011Ostroukhova
Frontiers in Chemistry | www.frontiersin.org September 2021 | Volume 9 | Article 6851968
Santos et al. Hyperglycolysis Underlying COVID-19 Disease Severity
Paces, J., Strizova, Z., Smrz, D., and Cerny, J. (2020). COVID-19 and the immune
system. Physiol. Res. 69 (3), 379–388. doi:10.33549/physiolres10.33549/
physiolres.934492
Patel, C. H., Leone, R. D., Horton, M. R., and Powell, J. D. (2019). Targeting
metabolism to Regulate immune Responses in autoimmunity and cancer. Nat.
Rev. Drug Discov. 18 (9), 669–688. doi:10.1038/s41573-019-0032-5
Pfaffenbach, K. T., and Lee, A. S. (2011). The critical Role of GRP78 in physiologic
and pathologic stress. Curr. Opin. Cel Biol. 23, 150–156. doi:10.1016/
j.ceb.2010.09.007
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., et al. (2020). Dysregulation of
Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan,
China. Clin. Infect. Dis. 71, 762–768. doi:10.1093/cid/ciaa248
Reckzeh, E. S., and Waldmann, H. (2020). Development of Glucose Transporter
(GLUT) Inhibitors. Eur. J. Org. Chem. 2020 (16), 2321–2329. doi:10.1002/
ejoc.2019013510.1002/ejoc.201901353
Sabirli, R., Koseler, A., Goren, T., Turkcuer, I., and Kurt, O. (2021). High GRP78
levels in COVID-19 infection: a case-control study. Life Sci. 265, 118781.
doi:10.1016/l.lfs.2020.11878110.1016/j.lfs.2020.118781
Saleh, J., Peyssonnaux, C., Singh, K. K., and Edeas, M. (2020). Mitochondria and
microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion 54, 1–7.
doi:10.1016/j.mito.2020.06.008
Sasaki, K., Nishina, S., Yamauchi, A., Fukuda, K., Hara, Y., Yamamura, M., et al.
(2021). Nanoparticle-mediated delivery of 2-deoxy-D-glucose induces
antitumor immunity and cytotoxicity in liver tumors in mice. Cell Mol.
Gastroenterol. Hepatol. 11, 739–762. doi:10.1016/j.jcmgh.2020.10.010
Schultheiss, C., Paschold, L., Simnica, D., Mohme, M., Willscher, E., von
Wenserski, L., et al. (2020). Next-generation sequencing of T and B cell
Receptor Repertoires from COVID-19 patients showed signatures associated
with severity of disease. Immunity 53, 442–e4. doi:10.1016/
j.immuni.2020.06.024
Seheult, J., Fitzpatrick, G., and Boran, G. (2017). Lactic acidosis: an Update. Clin.
Chem. Lab. Med. 55 (3), 322–333. doi:10.1515/cclm-2016-0438
Serebrovska, Z. O., Chong, E. Y., Serebrovska, T. V., Tumanovska, L. V., and Xi, L.
(2020). Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential
therapeutic targets. Acta Pharmacol. Sin 41 (12), 1539–1546. doi:10.1038/
s41401-020-00554-8
Singh, D., Banerji, A. K., Dwarakanath, B. S., Tripathi, R. P., Gupta, J. P., Mathew,
T. L., et al. (2005). Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose.
Strahlenther Onkol 181, 507–514. doi:10.1007/s00066-005-z10.1007/s00066-
005-1320-z
Sinha, P., Matthay, M. A., and Calfee, C. S. (2020). Is a "Cytokine Storm" Relevant
to COVID-19?. JAMA Intern. Med. 180 (9), 1152–1154. doi:10.1001/
jamainternmed.2020.3313
Strachecka, A., Grzybek, M., Ptaszynska, A. A., Los, A., Chobotow, J., and
Rowinski, R. (2019). Comparison of Lactate Dehydrogenase Activity in Hive
and Forager Honeybees May Indicate Delayed Onset Muscle Soreness -
Preliminary Studies. Biochem. Mosc. 84 (4), 435–440. doi:10.1134/
S0006297919040114
Suhail, S., Zajac, J., Fossum, C., Lowater, H., McCracken, C., Severson, N., et al.
(2020). Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2
(COVID-19) Infection: A Review. Protein J. 39 (6), 644–656. doi:10.1007/
s10930-020-09935-8
Taher, A., Lashgari, M., Sedighi, L., Rahimi-Bashar, F., Poorolajal, J., and
Mehrpooya, M. (2021). A pilot study on intravenous N-Acetylcysteine
treatment in patients with mild-to-moderate COVID19-associated acute
Respiratory distress syndrome. Pharmacol. Rep., 1–10. doi:10.1007/s43440-
021-00296-2
Tang, X., Du, R.-H., Wang, R., Cao, T.-Z., Guan, L.-L., Yang, C.-Q., et al. (2020).
Comparison of Hospitalized Patients with ARDS Caused by COVID-19 and
H1N1. Chest 158 (1), 195–205. doi:10.1016/j.chest.2020.03.032
Tian, S., Liu, H., Liao, M., Wu, Y., Yang, C., Cai, Y., et al. (2020). Analysis of
Mortality in Patients with COVID-19: Clinical and Laboratory Parameters.
Open Forum Infect. Dis. 7 (5), 7. doi:10.1093/ofid/ofaa152
Vanderheiden, A., Ralfs, P., Chirkova, T., Upadhyay, A. A., Zimmerman, M. G.,
Bedoya, S., et al. (2020). Type I and type III interferons Restrict SARS-CoV-2
infection of human airway epithelial cultures. J. Virol. 94, e00985–20.
doi:10.1128/JVI.00985-20
Verma, A., Adhikary, A., Woloschak, G., Dwarakanath, B. S., and Papineni, R. V. L.
(2020). A combinatorial approach of a polypharmacological adjuvant 2-deoxy-
D-glucose with low dose Radiation therapy to quell the cytokine storm in
COVID-19 management. Int. J. Radiat. Biol. 96 (11), 1323–1328. doi:10.1080/
09553002.2020.1818865
Wong, K. K., Lee, S. W. H., and Kua, K. P. (2021). N-Acetylcysteine as Adjuvant
Therapy for COVID-19 - A Perspective on the Current State of the Evidence. Jir
Vol. 14, 2993–3013. doi:10.2147/JIR.S306849
Woodward, G. E., and Cramer, F. B. (1952). 2-Desoxyl-D-glucose as an inhibitor of
anaerobic glycolysis in tumor tissue. J. Franklin Inst. 254, 259–260. doi:10.1016/
0016-0032(52)90482-1
Yang, W.-H., Park, H., Grau, M., and Heine, O. (2020). Decreased Blood Glucose
and Lactate: Is a Useful Indicator of Recovery Ability in Athletes?. Ijerph 17
(15), 5470. doi:10.3390/ijerph17155470
Ye, Q., Wang, B., and Mao, J. (2020). The pathogenesis and treatment of the
`Cytokine Storm’ in COVID-19. J. Infect. 80, 607–613. doi:10.1016/
j.jinf.2020.03.037
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., and Slutsky, A. S. (2020).
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 Receptor:
molecular mechanisms and potential therapeutic target. Intensive Care Med.
46 (4), 586–590. doi:10.1007/s00134-020-05985-9
Zhang, Q., Ju, Y., Ma, Y., andWang, T. (2018). N-acetylcysteine improves oxidative
stress and inflammatory Response in patients with community acquired
pneumonia: a Randomized controlled trial. Medicine (Baltimore) 97,
e13087–1541. doi:10.1183/09031936.97.1007153510.1097/
MD.0000000000013087
Zhang, W., Wang, G., Xu, Z.-G., Tu, H., Hu, F., Dai, J., et al. (2019). Lactate is a
Natural suppressor of RLR signaling by targeting MAVS. Cell 178, 176–189.
e.115. doi:10.1016/j.cell.2019.05.003
Zhang, Z.-L., Hou, Y.-L., Li, D.-T., and Li, F.-Z. (2020). Laboratory findings of
COVID-19: a systematic Review and meta-analysis. Scand. J. Clin. Lab. Invest.
80 (6), 441–447. doi:10.1080/00365513.2020
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A Novel
Coronavirus from Patients with Pneumonia in China, 2019.N. Engl. J. Med. 382
(8), 727–733. doi:10.1056/NEJMoa2001017
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Santos, Póvoa, Paixão, Mendonça and Taborda-Barata. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Chemistry | www.frontiersin.org September 2021 | Volume 9 | Article 6851969
Santos et al. Hyperglycolysis Underlying COVID-19 Disease Severity
